<!DOCTYPE html>
<html>
  <head>
    <title>Stopping and Preventing Errors in CMV-negative and Irradiated blood transfusions through App-based Learning (SPECIAL)</title>
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <link rel="stylesheet" href="http://code.jquery.com/mobile/1.4.2/jquery.mobile-1.4.2.min.css" />
    <script src="http://code.jquery.com/jquery-1.9.1.min.js"></script>
    <script src="http://code.jquery.com/mobile/1.4.2/jquery.mobile-1.4.2.min.js"></script>
    <style>
      .special {color: #C00; text-decoration: underline; font-weight: bold;}
      .noline {text-decoration: none;font-style: italic;}
      legend, p {font-size: 1.2em;}
    </style>
    
        
    <!-- Google Analytics -->
    
    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','//www.google-analytics.com/analytics.js','ga');
      var sessionID = "0";
      ga('create', 'UA-44958852-1', 'optimalblooduse.eu');
      ga(function(tracker) {
        sessionID = tracker.get('clientId');
        ga('set', 'dimension1', sessionID);
        //$("#buttons").append('<a style="background:#5d5;" rel="external" href="randomise.php?s=' + sessionID + '&b=g" data-role="button">Greater Glasgow and Clyde</a>').append('<a style="background:#5d5;" href="randomise.php?s=' + sessionID + '&b=o" data-role="button" rel="external">Other Scottish Health Board</a>').trigger("create");
        
        
      });
      ga('send', 'pageview');
    
    </script>
    
    <!-- End Google Analytics -->

  </head>
  
  <body style="padding: 10px;">
    
    <div data-role="page" style="background:  #1A5A5A; padding-top: 20px;">

        <div data-role="main" class="ui-content" style="background: #ffe; margin: 0pc auto; max-width: 900px; border: 5px solid #333; border-radius: 5px;">

	<center>      
        <h1>Welcome to <span class="special noline">SPECIAL</span></h1>
        </center>
        <p style="font-size: 1.3em; margin: 1em; border: 1px dashed; padding: 0.5em; border-radius: 3px;"><span class="special">S</span>topping and <span class="special">P</span>reventing <span class="special">E</span>rrors in <span class="special">C</span>MV-negative and <span class="special">I</span>rradiated blood transfusions through <span class="special">A</span>pp-based <span class="special">L</span>earning.</p>
        
        <p style="background:#FD5; text-align: center; margin: 1em; border: 0px dashed; padding: 0.5em; border-radius: 3px;"><strong>The trial is currently <span style="text-decoration: line-through;">actively recruiting</span> under development.</strong></p>

        <center>
          <h1>1. Introduction</h1>
        </center>

        <p style="display: none;">This is the home page for the Scottish <span class="special noline">SPECIAL</span> online clinical trial.</p>
 
        <p>Although blood transfusion in the UK is safe, it is a complex process and mistakes can occur at various stages. The <span class="special noline">SPECIAL</span> trial will investigate the effectiveness of an app-based learning intervention in reducing errors in the prescription of irradiated and CMV-negative blood components by doctors and nurse authorisers in Scotland.</p>

	<p> Expand the sections to show more details about the study.</p>

        <div data-role="collapsibleset" data-inset="false">
          
          <div data-role="collapsible" data-collapsed="true">          
              
            <h2>1.1 Rationale</h2>

            <p>Approximately one hundred mistakes related to the provision of irradiated and CMV-negative blood components (special requirements) are reported every year to the SHOT UK haemovigilance scheme (cf. Bolton-Maggs 2012).</p>
            
            <p>These mistakes put patients at unnecessary risk of developing transfusion-associated Graft versus Host Disease (TA-GvHD). TA-GvHD is a rare lethal condition that can be avoided by irradiating cellular blood components (Treleaven et al. 2010).</>
            
            <p>Additionally, transfusion can transmit cytomegalovirus (CMV) infection, which can lead to serious conditions in vulnerable patients. CMV-negative blood components should therefore be provided to high risk patients (SaBTO 2012).</p>
            
          </div>


          <div data-role="collapsible">
          
            <h2>1.2 Objectives</h2>
		<p>The trial seeks to answer the following questions:</p>
        
            <ol>

              <li>What is the current state of knowledge about special requirements among doctors and nurses who prescribe blood?<br/><br/></li>

              <li>How do access to a mobile app and existing guidelines influence prescription of irradiated and CMV-negative blood?<br/><br/></li>

              <li>How do clinicians rate the quality, ease of use and utility of the mobile app?<br/><br/></li>
            
              <li>Do participants gain and retain new knowledge or awareness about special requirements after completing the trial?</li>

            </ol>
            
          </div>
          
          <div data-role="collapsible">
            <h2>1.3 Methodology</h2>
            <h3>Summary</h3>
            <p>Web-based randomised controlled trial of blood component prescribing in simulated clinical scenarios when supported by:</p>
            <ol>
              <li>Local and/or national guidelines (current recommended practice, control group).<br/><br/></li>
              <li>An app with learning material (experimental treatment).</li>
            </ol>
            <h3>Details</h3>
  	      <p>Participants answer a baseline test of knowledge without access to the app or guidelines. They are then randomised to either app or guideline (displayed on screen with the questions) and tested again.</p>
              <p>At the end of the second test, participants are asked to provide details about their professional experience and demographics. Those randomised to the app, are additionally requested to complete a short survey to rate its quality, ease of use and utility.</p>
              <p>Finally, participants are invited to take part in a follow-up baseline test one month later.</p>
            </div>
          
          <div data-role="collapsible">
            <h2>1.4 Protocol</h2><center>
            <img src="newesttrialdesign2.png" style="padding-top: 10px; max-width:800px; width: 100%"/></center>
          </div>
          
          
          <div data-role="collapsible">
            <h2>1.5 Investigators</h2>
            
            <p><strong>Karl Monsen</strong><br>
            5.17, Evolution House<br/>
            78 West Port<br/>
            Design Informatics<br/>
            School of Design</br>
            Edinburgh College of Art<br/>
            University of Edinburgh<br/>
            EH1 2LE<br/><br/>
            Karl is a PhD candidate at The University of Edinburgh, investigating the design, use and evaluation of apps in medicine. He is developing an app aiming to improve the prescription of irradiated and CMV-negative blood components.<br/>
            Email: <a href="mailto:kd.monsen@sms.ed.ac.uk" data-role="button" data-inline="true">kd.monsen@sms.ed.ac.uk</a><br/>
            <hr/>
            <p><strong>Dr. Brian McClelland</strong><br/>
            Dr. McClelland is medical adviser to the project. He is the editor of the fourth edition of the Handbook of Transfusion Medicine and a widely published expert in blood transfusion.</p>  
            <hr/>
            <p><strong>Acknowledgements</strong><br/>
            <p>This trial is supported by additional advisors at the University of Edinburgh and the Better Blood Transfusion team at the Scottish National Blood Transfusion Service.</p>
          </div>


          <div data-role="collapsible">
            <h2>1.6 References </h2>
	    <ul>
	    	<li>Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO) (2012) Position statement on cytomegalovirus tested blood components.<br/><br/></li>
		<li>Bolton-Maggs P (Ed), Poles D, Watt A, Thomas D and Cohen H (2013) on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2012 Annual SHOT Report.<br/><br/></li>
	        <li>Green, J and Pirie, L (2009)  A Framework to Support Nurses and Midwives. Transfusion Guidelines. Available from http://www.transfusionguidelines.org.uk/docs/pdfs/BTFramework-final010909.pdf<br/><br/></li>
		<li>Treleaven, J., Gennery, A., Marsh, J., Norfolk, D., Page, L., Parker, A., Saran, F., Thurston, J. and Webb, D. (2011), Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. British Journal of Haematology, 152: 35-51. doi: 10.1111/j.1365-2141.2010.08444.x</li>
	  </div>


          
        </div>
          
      
        <center>
          <h1>2. Elegibility</h1>
        </center>

        <p>We are looking for doctors and nurses who prescribe blood in Scotland. If you match the inclusion criteria, please read the terms of participation and consider taking part.</p>


        <div data-role="collapsibleset" data-inset="false">

          <div data-role="collapsible">
            <h2>2.1 Inclusion criteria</h2>
            
            <p>Inclusion criteria:</p>
            <ul>
              <li>Doctors who prescribe blood transfusion and who are working in Scotland.</li>
              <li>Nurse authorisers* who prescribe blood transfusion and who are working in Scotland.</li>
            </ul>
            <p>Exclusion criteria:</p>
            <ul>
              <li>Healthcare staff who do not have blood transfusion authoriser status.</li>
              <li>Nurses and doctors working outside of Scotland.</li>
            </ul>
            <p>* <span style="font-size: 0.6em;">Following an amendment to the 1968 Medicines Act, blood is excluded from the legal definition of medicinal product. Trained nurse authorisers can therefore authorise blood transfusions (c.f. Green & Pirie 2009).</span></p>
          </div>


        
          <div data-role="collapsible">
            <h2>2.2 Terms of participation</h2>
<span style="display: none">
            <p>If you choose to participate, you will be asked to:</p>
            
            <ol>
              <li>Answer a short pre-test about irradiated and CMV-negative blood components.</li>
              <li>Briefly explore local and national guidelines or a mobile app.</li>
              <li>Answer a short post-test on the same topic.</li>
              <li>Evaluate the quality of the resource you accessed.</li>
              <li>Provide details about your professional background, such as specialties worked in.</li>
              <li>Complete a follow up test one month later on the same topic.</li>
            </ol>
            </span>

            <p>What data is collected?</p>
            
            <ol>
              <li>Answers you provide to questions will be recorded.</li>
	      <li>The system records how long you take to answer and if you make use of the app or guidelines.</li>
              <li>Personally identifiable data is not collected.</li>
	      <li>But if you wish to participate in the follow up test, you will be asked to enter your email address.</li>
	      <li>Your email address will be used to contact you about the follow up test and will not be shared.</li>
            </ol>

            <p>How will the data be used?</p>

            <ol>
              <li>Any data you provide will be treated confidentially.</li>
              <li>Your answers will be reported anonymously in any publications.</li>
              <li>Data will be held securely for the duration of the research project (3 years) and then destroyed.</li>
              <li>You may withdraw from the research at any time for any reason. Your participation is voluntary.</li>
            </ol>
            <p>Please contact the investigators if you have questions about the above.</p>

          </div>

        </div>

	<center>
          <h1>3. Participate</h1>
	</center>
	<p><b>Please select your role and health board, and press the green button to enroll in the trial.</b></p>
	
	<form action="random.php" method="get" data-ajax="false" target="_blank">

	<div data-role="fieldcontain">

 	<fieldset data-role="controlgroup" data-theme="a">
	  <legend>Role (tick):</legend>
     	  <input type="radio" name="role" id="doctor" value="doctor"/>
     	  <label for="doctor">Doctor</label>

     	  <input type="radio" name="role" id="nurse" value="nurse"  />
     	  <label for="nurse">Nurse authoriser</label>

          <input type="radio" name="role" id="other" value="other"  />
     	  <label for="other">Other role authorised to prescribe transfusion</label>
        </fieldset>

	</div>

	<div data-role="fieldcontain">

        <fieldset data-role="controlgroup" data-theme="a">
          <legend>Health board:</legend>
          <input type="radio" name="healthboard" id="glasgow" value="glasgow"/>
          <label for="glasgow">Greater Glasgow and Clyde</label>

          <input type="radio" name="healthboard" id="scotland" value="scotland"  />
          <label for="scotland">Other Scottish health board</label>
        </fieldset>
	</div>
<br/>
        <p>By proceeding you indicate that you agree to the terms of participation and give your informed consent to take part in the research.</p>
  <br/>  
	<button type="submit" style="background: #4C4;" data-theme="b">Enroll in trial</button>

	</form>

  <br/>  
  <br/>  
      </div>
  <p style="text-align: center; font-size: 0.8em; text-shadow: none; color: white">Last modified: April 2014</p>
  <br/>  
  <br/>  
    </div>

  </body>
</html>
